Psychology's role in health in Canada: Reaction to Romanow and Marchildon

Canadian Psychology

Volumn 45, Issue 3, 2004, Pages 228-232

  Arnett, John L ^a,d   Nicholson, Ian R ^b   Breault, Lorraine ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4043181290     PISSN: 07085591     EISSN: None     Source Type: Journal    
DOI: 10.1037/h0086991     Document Type: Review

References (27)

1. Antonuccio, D. O., Danton, W. G., & DeNelsky, G. Y. (1995). Psychotherapy versus medication for depression: Challenging the conventional wisdom with data. Professional Psychology: Research and Practice, 26(6), 574-585.
2. Antonuccio, D. O., Thomas, M., & Danton, W. G. (1997). A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. Behavior Therapy, 28, 187-210.
3. Barlow, D. H., German, J. M., Shear, M. K., & Woods, S. W. (2000). Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association, 283(19), 2529-2536.
4. Canada (1974). A new perspective on the health of Canadians; A working document [Lalonde Report]. Ottawa, ON: Department of National Health and Welfare.
5. Casacalenda, N., Perry, J. C., & Looper, K. (2002). Remission in major depressive disorder: A comparison of pharmacotherapy, psychotherapy, and control conditions. American Journal of Psychiatry, 159, 1354-1360.
6. Chiles, J. A., Lambert, M. J., & Hatch, A. L. (1999). The impact of psychological interventions on medical cost offset: A meta-analytic review. Clinical Psychology: Science and Practice, 6(2), 204-220.
7. DeRubeis, R. J., Gelfand, L. A., Tang, T. Z. & Simons, A. D. (1999). Medications versus cognitive therapy for severely depressed outpatients: Mega-analysis of four randomized comparisons. The American Journal of Psychiatry, 156, 1007-1013.
8. Desmond, D. W., Moroney, J. T., Bagiella, E., Sano, M., & Stern, Y. (1998). Dementia as a predictor of adverse outcomes following stroke: An evaluation of diagnostic methods. Stroke, 29, 69-74.
9. Dusseldorp, E., van Elderen, T., Maes, S., Meulman, J., & Kraaij, V. (1999). A meta-analysis of psychoeducational programs for coronary heart disease patients. Health Psychology, 18(5), 506-519.
10. Dwight-Johnson, M., Sherbourne, C. D., Liao, D., & Wells, K. B. (2000). Treatment preferences among depressed primary care patients. Journal of General Internal Medicine, 15, 527-534.
11. Gould, R. A., Otto, M. W., & Pollack, M. H. (1996). A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review, 15(8), 819-844.
12. Haug, T. T., Blomhoff, S., Hellstrom, K., Holme, I., Humble, M., Madsbu, H. P., et al. (2003). Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomized controlled trial. The British Journal of Psychiatry, 182, 312-318.
13. Heart and Stroke Foundation of Canada (1999, October). The changing face of heart disease and stroke in Canada 2000. Ottawa, ON: Health Canada.
14. Hunsley, J. (2003). Cost-effectiveness and medical cost-offset considerations in psychological service provision. Canadian Psychology, 44, 61-73.
15. Jacobs, D. F. (1987). Cost-effectiveness of specialized psychological programs for reducing hospital stays and outpatient visits. Journal of Clinical Psychology, 43(6), 729-735.
16. Jarrett, R. B., Schaffer, M., McIntire, D., Witt-Browder, A., Kraft, D., & Risser, R. C. (1999). Treatment of atypical depression with cognitive therapy or phenelzine: A double-blind, placebo-controlled trial. Archives of General Psychiatry, 56, 431-437.
17. Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., et al. (2000). A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. The New England Journal of Medicine, 342(20), 1462-1470.
18. Otto, M. W. Pollack, M. H., & Maki, K. M. (2000). Empirically supported treatments for panic disorder: Costs, benefits, and stepped care. Journal of Consulting and Clinical Psychology, 68(4), 556-563.
19. Otto, M. W., Pollack, M. H., & Sabatino, S. A. (1996). Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment. Behavior Therapy, 27, 473-482.
20. Romanow, R. J., & Marchildon, G. P. (2003). Psychological services and the future of health care in Canada. Canadian Psychology, 44, 283-295.
21. Satcher, D. (1998, November 12). Building the next generation of healthy people. Keynote address to the National Healthy People Consortium Meeting and Public Hearing. Washington, DC.
22. U.S. Department of Health and Human Services (2000). Healthy People 2010: Understanding and improving health. Washington, DC: Government Printing Office.
23. Valdivia, I., & Rossy, N. (2004). Brief treatment strategies for major depressive disorder: Advice for the primary care clinician. Topics in Advanced Nursing Practice eJournal, 4(1).
24. Walker, J. R., Ediger, J., Joyce, B., Furer, P., Vincent, N., & Kjernisted, K. (2001, March). A survey of preference for pharmacological and psychological treatment for anxiety problems in an Anxiety Disorders Clinic. Poster session presented at the Anxiety Disorders Association of America, 21st National Conference, Atlanta, GA.
25. Westen, D., & Morrison, K. (2001). A multidimensional meta-analysis of treatments of depression, panic, and generalized anxiety disorder: An empirical examination of the status of empirically supported therapies. Journal of Consulting and Clinical Psychology, 69(6), 875-899.
26. Westra, H. A., & Stewart, S. H. (1998). Cognitive behavioural therapy and pharmacotherapy: Complementary or contradictory approaches to the treatment of anxiety. Clinical Psychology Review, 15(3), 307-340.
27. World Health Organization (2002). The World Health Report 2002: Reducing risks, promoting healthy lifestyles. Geneva: World Health Organization.